Braveheart Bio (NASDAQ:BRVE) Shares Up 4.3% – Should You Buy?

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report)’s share price traded up 4.3% during mid-day trading on Friday. The company traded as high as $20.14 and last traded at $20.0960. Approximately 151,967 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 470,956 shares. The stock had previously closed at $19.27.

Wall Street Analyst Weigh In

BRVE has been the topic of several research analyst reports. TD Cowen started coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating on the stock. Jefferies Financial Group began coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Zacks Research upgraded Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. The Goldman Sachs Group initiated coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, Weiss Ratings assumed coverage on Braveheart Bio in a research report on Monday, November 2nd. They issued a “sell (d-)” rating for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Braveheart Bio currently has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Get Our Latest Analysis on BRVE

Braveheart Bio Stock Performance

The firm’s 50-day moving average is $21.35. The firm has a market cap of $1.87 billion and a price-to-earnings ratio of -6.77.

Braveheart Bio (NASDAQ:BRVE – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.40. Equities analysts anticipate that Braveheart Bio, Inc. will post -1.97 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Readystate Asset Management LP purchased a new stake in shares of Braveheart Bio in the 3rd quarter valued at approximately $202,000. Ghisallo Capital Management LLC purchased a new position in shares of Braveheart Bio during the third quarter worth about $404,000. Goldman Sachs Group Inc. acquired a new stake in shares of Braveheart Bio during the third quarter worth $841,000. Integral Health Asset Management LLC purchased a new position in Braveheart Bio during the third quarter worth about $2,020,000. Finally, RA Capital Management L.P. purchased a new stake in Braveheart Bio during the third quarter worth about $11,413,000.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

See Also

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.